Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.63 |
| ▸ | NPY1R | P25929 | 9/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.63 |
| ▸ | NPY2R | P49146 | 5/20 | 0.63 |
| ▸ | TFPI | P10646 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 2/20 | 0.55 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.55 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30782714 | 0.90 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL31047374 | 0.90 | TFPI (0.66) | TFPIBACE1BACE2VIPR1 | |
| SCHEMBL4449035 | 0.90 | NPY4R (0.74) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL30262077 | 0.90 | TFPI (0.67) | TFPIBACE1BACE2VIPR1 | |
| SCHEMBL32664388 | 0.89 | TFPI (0.65) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29835241 | 0.89 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29558454 | 0.88 | TFPI (0.69) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL30849955 | 0.88 | NPY4R (0.76) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30804481 | 0.88 | NPY4R (0.76) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29580062 | 0.88 | VIPR1 (0.63) | NPY4RNPY1RNPY5RNPY2RBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146083-A1 | Methods of Treating Kawasaki Disease Using IL-1beta Antibodies | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-20260125463-A1 | Methods of Using IL-1beta Compounds | NOVARTIS AG (CH) | 2026-05-07 | — | — | US | disclosed |
| US-20240083997-A1 | Methods of Using IL-1beta Compounds | NOVARTIS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| EP-4218815-A2 | USE OF ANTI IL-1BETA ANTIBODIES | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-4177268-A2 | NEW INDICATIONS FOR ANTI-IL-1BETA THERAPY | Novartis AG (CH) | 2023-05-10 | — | — | EP | disclosed |
| EP-3332807-B1 | USE OF ANTI IL-1BETA ANTIBODIES | NOVARTIS AG (CH) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146083-A1 | Methods of Treating Kawasaki Disease Using IL-1beta Antibodies | IL1A, IL1R1, FCGR2A | NPY4R 2932/4885NPY1R 925/4885NPY5R 3511/4885 |
| US-20260125463-A1 | Methods of Using IL-1beta Compounds | IL1B, IL1RN, IL1A | NPY4R 1541/4885NPY1R 463/4885NPY5R 1494/4885 |
| US-20240083997-A1 | Methods of Using IL-1beta Compounds | IL1RN, IL1A, IL1B | NPY4R 2125/4885NPY1R 833/4885NPY5R 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.